Maheshwari Ramineni
Overview
Explore the profile of Maheshwari Ramineni including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
358
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shen Y, Raza R, Ramineni M, Marginean C, Sur N, Wang B
Diagn Cytopathol
. 2025 Mar;
53(4):E66-E69.
PMID: 40026176
Glomus tumors are benign vascular soft tissue neoplasms of glomus bodies. Primary lung glomus tumors are rare and usually express smooth muscle markers, and are negative for cytokeratin and neuroendocrine...
2.
Mitra S, Jang H, Kuncheria A, Kang S, Choi J, Shim J, et al.
J Thorac Cardiovasc Surg
. 2024 Oct;
PMID: 39395787
Background: Immune checkpoint therapy (ICT) has significantly impacted the treatment of malignant pleural mesothelioma (MPM). Despite some promising results from combination therapies, nearly half of MPM patients do not benefit,...
3.
Lee H, Jang H, Ramineni M, Wang D, Ramos D, Choi J, et al.
Clin Cancer Res
. 2022 Dec;
29(3):548-559.
PMID: 36469573
Purpose: We report the results of a phase II, randomized, window-of-opportunity trial of neoadjuvant durvalumab versus durvalumab plus tremelimumab followed by surgery in patients with resectable malignant pleural mesothelioma (MPM;...
4.
Kumar A, Li G, Segraves J, Mattar A, Ramineni M, Loor G, et al.
Pediatr Transplant
. 2022 Jul;
26(8):e14351.
PMID: 35799318
Background: SARS-CoV-2 infection in the age group of 0-17 years contributes to approximately 22% of all laboratory-confirmed SARS-CoV-2 infections. Fortunately, this age group has a lower death rate (0.5 per...
5.
Jang H, Lee H, Yu W, Ramineni M, Truong C, Ramos D, et al.
Cancer Res
. 2022 Jun;
82(14):2593-2609.
PMID: 35709756
Comprehensive single-cell proteomics analyses of lung adenocarcinoma progression reveal the role of tumor-associated macrophages in resistance to PD-1 blockade therapy. See related commentary by Lee et al., p. 2515.
6.
Tang M, Abbas H, Negrao M, Ramineni M, Hu X, Hubert S, et al.
Nat Commun
. 2021 Dec;
12(1):7081.
PMID: 34873156
Histology plays an essential role in therapeutic decision-making for lung cancer patients. However, the molecular determinants of lung cancer histology are largely unknown. We conduct whole-exome sequencing and microarray profiling...
7.
Jang H, Truong C, Lo E, Holmes H, Ramos D, Ramineni M, et al.
Ann Thorac Surg
. 2021 Sep;
114(5):1842-1852.
PMID: 34592265
Background: Despite the profound number of malignant pleural mesothelioma (MPM) patients now treated with programmed cell death 1 (PD-1) blockade, insight into the underpinnings of rational therapeutic strategies to treat...
8.
Surman D, Xu Y, Lee M, Trepel J, Brown K, Ramineni M, et al.
Mol Cancer Ther
. 2021 Jun;
20(8):1469-1480.
PMID: 34088830
Approximately 20,000 patients per year are diagnosed with esophageal adenocarcinoma (EAC) and malignant pleural mesothelioma (MPM); fewer than 20% survive 5 years. Effective therapeutic strategies are limited although patients receive...
9.
Lee H, Hamaji M, Palivela N, Jang H, Splawn T, Ramos D, et al.
Ann Thorac Surg
. 2020 Nov;
112(5):1575-1583.
PMID: 33248997
Background: The prognostic role of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM) is incompletely understood. Our objectives were to evaluate the evidence for tumor PD-L1...
10.
Candelaria R, Bassett R, Symmans W, Ramineni M, Moulder S, Kuerer H, et al.
Oncologist
. 2017 Mar;
22(4):394-401.
PMID: 28314842
Background: The primary objective was to determine whether mid-treatment ultrasound measurements of index breast tumors and index axillary nodes of different cancer subtypes associate with residual cancer burden (RCB). Methods:...